Guidelines are too important to be left to clinical experts

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 2, 2012, Pages 159-160

  Johansson, Mattias ^a   Stattin, Pär ^b,c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RECURRENCE; EVIDENCE BASED MEDICINE; MEDICAL DECISION MAKING; MEDICAL EXPERT; NOTE; PATIENT MONITORING; PRACTICE GUIDELINE; PROSTATE CANCER;

EID: 84856799530     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111989     Document Type: Note

References (12)

1. Dinnes J, Hewison J, Altman D, et al. The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer. CMAJ 2012;184:169- 77.
2. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12:18-23.
3. The National Institute for Health and Clinical Excellence. Pro state cancer: diagnosis and treatment. London (UK): The Institute; 2008.
4. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
5. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
6. van den Bergh RC, Roemeling S, Roobol MJ, et al. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007;52:1560-3. (Pubitemid 350052404)
7. World Health Organization. A Swedish trial comparing two different follow-up schedules for patients with low-risk prostate cancer on active surveillance with selective, delayed treatment SAMS-FU. Geneva (Switzerland): The Organization; 2011. Available: http://apps. who. int /trialsearch /trial. aspx ?trialid =ISRCTN64891728 (accessed 2011 Nov. 28).
8. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
9. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
10. Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol 2009;43:342-9.
11. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456-77. (Pubitemid 350207540)
12. Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950-8.